Back to top
more

Agios Pharmaceuticals, Inc. (AGIO)

(Delayed Data from NSDQ)

$47.14 USD

47.14
1,126,643

+1.34 (2.93%)

Updated Sep 17, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (208 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for AGIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Agios Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 573 565 585 424 541
Receivables 25 15 10 4 8
Notes Receivable 0 0 0 0 0
Inventories 15 7 1 0 0
Other Current Assets 24 24 17 17 10
Total Current Assets 637 612 614 445 560
Net Property & Equipment 32 31 24 24 25
Investments & Advances 98 153 220 144 32
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 1 0 0 1 2
Total Assets 853 891 858 614 619
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 27 22 18 23 17
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 60 53 42 34 32
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 11 33 38 39
Total Current Liabilities 94 93 94 95 88
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 51 77 144 172
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 1 0 0 0
Other Non-Current Liabilities 261 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 453 250 171 239 261
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,243 2,156 1,794 1,175 842
Retained Earnings -1,843 -1,516 -1,105 -798 -483
Other Equity 0 0 -2 -1 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 400 641 688 376 359
Total Liabilities & Shareholder's Equity 853 891 858 614 619
Total Common Equity 400 641 688 376 359
Shares Outstanding 69.30 58.80 58.10 48.80 42.00
Book Value Per Share 5.76 10.89 11.83 7.69 8.54

Fiscal Year End for Agios Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Assets          
Cash & Equivalents 1,673 2,336 573 606 790
Receivables 8 0 25 23 18
Notes Receivable 0 0 0 0 0
Inventories 0 0 15 11 11
Other Current Assets 21 20 24 29 27
Total Current Assets 1,703 2,355 637 669 846
Net Property & Equipment 27 29 32 34 34
Investments & Advances 61 22 98 117 4
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 3 0 1 1 2
Total Assets 1,875 2,488 853 908 976
Liabilities & Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Notes Payable 0 0 0 0 0
Accounts Payable 8 51 27 13 15
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 0 0 0 0
Accrued Expenses 36 24 60 50 42
Income Taxes Payable 7 13 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 61 97 94 70 64
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 261 258 251
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 153 192 453 428 418
Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,306 2,266 2,243 2,226 2,204
Retained Earnings -55 31 -1,843 -1,746 -1,647
Other Equity -0 0 0 1 2
Treasury Stock 529 0 0 0 0
Total Shareholder's Equity 1,722 2,297 400 480 558
Total Liabilities & Shareholder's Equity 1,875 2,488 853 908 976
Total Common Equity 1,722 2,297 400 480 558
Shares Outstanding 58.90 61.50 69.30 69.20 69.10
Book Value Per Share 29.23 37.34 5.76 6.94 8.08